ResMed (RMD) Financials

$246.26 +3.42 (+1.41%)

Closing price 03:59 PM Eastern

Extended Trading

$246.32 +0.06 (+0.03%)

As of 06:57 PM Eastern

Annual Income Statements for ResMed

This table shows ResMed's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	6/30/2024	6/30/2023	6/30/2022	6/30/2021	6/30/2020	6/30/2019	6/30/2018	6/30/2017	6/30/2016	6/30/2015
Net Income / (Loss) Attributable to Common Shareholders	1,021	898	779	475	622	405	316	342	352	353
Consolidated Net Income / (Loss)	1,021	898	779	475	622	405	316	342	352	353
Net Income / (Loss) Continuing Operations	1,021	898	779	475	622	405	316	342	352	353
Total Pre-Tax Income	1,265	1,102	960	884	733	519	521	419	440	436
Total Operating Income	1,320	1,132	1,000	904	810	579	542	426	429	409
Total Gross Profit	2,655	2,356	2,024	1,839	1,718	1,494	1,335	1,202	1,066	1,011
Total Revenue	4,685	4,223	3,578	3,197	2,957	2,607	2,340	2,067	1,839	1,679
Operating Revenue	4,685	4,223	3,578	3,197	2,957	2,607	2,340	2,067	1,839	1,679
Total Cost of Revenue	2,030	1,867	1,554	1,358	1,239	1,113	1,005	865	772	668
Operating Cost of Revenue	2,030	1,867	1,554	1,358	1,239	1,113	1,005	865	772	668
Total Operating Expenses	1,335	1,224	1,024	935	908	915	793	776	638	602
Selling, General & Admin Expense	917	874	738	670	677	645	600	554	488	479
Research & Development Expense	308	288	254	225	202	181	155	144	119	115
Amortization Expense	47	42	31	31	30	32	19	47	24	8.67
Restructuring Charge	64	20	1.86	8.67	0.00	9.40	18	22	6.91	0.00
Total Other Income / (Expense), net	-55	-30	-40	-20	-77	-60	-21	-7.06	11	27
Interest & Investment Income	-48	-55	-31	-11	-25	-14	16	17	17	26
Other Income / (Expense), net	-7.54	24	-9.01	15	-12	-11	-8.54	4.10	4.96	6.25
Income Tax Expense	244	204	181	409	111	114	206	76	87	83
Basic Earnings per Share	$6.94	$6.12	$5.34	$3.27	$4.31	$2.83	$2.21	$2.42	$2.51	$2.51
Weighted Average Basic Shares Outstanding	147.02M	146.77M	146.07M	145.31M	144.34M	143.11M	142.76M	141.36M	140.24M	140.47M
Diluted Earnings per Share	$6.92	$6.09	$5.30	$3.24	$4.27	$2.80	$2.19	$2.40	$2.49	$2.47
Weighted Average Diluted Shares Outstanding	147.55M	147.46M	147.04M	146.45M	145.65M	144.48M	143.99M	142.45M	141.67M	142.69M
Weighted Average Basic & Diluted Shares Outstanding	146.93M	147.07M	146.42M	145.68K	144.90M	143M	142.80M	141.40M	140.40M	140.60M
Cash Dividends to Common per Share	$1.92	$1.76	$1.68	$1.56	$1.56	$1.48	$1.40	$1.32	$1.20	$1.12

This table shows ResMed's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	365	345	311	292	300	209	219	230	233	225	210
Consolidated Net Income / (Loss)	365	345	311	292	300	209	219	230	233	225	210
Net Income / (Loss) Continuing Operations	365	345	311	292	300	209	219	230	233	225	210
Total Pre-Tax Income	418	418	383	358	375	259	272	277	289	274	262
Total Operating Income	426	417	387	381	375	275	289	275	301	280	276
Total Gross Profit	766	751	717	716	693	647	600	617	618	580	541
Total Revenue	1,292	1,282	1,225	1,223	1,197	1,163	1,102	1,122	1,117	1,034	950
Total Cost of Revenue	525	531	507	508	504	516	502	505	499	454	409
Operating Cost of Revenue	525	531	507	508	504	516	502	505	499	454	409
Total Operating Expenses	340	334	330	334	318	372	311	342	317	300	265
Selling, General & Admin Expense	245	242	239	242	230	222	223	240	228	212	194
Research & Development Expense	84	81	80	81	77	74	76	78	76	70	63
Amortization Expense	11	11	11	11	11	12	12	12	12	9.56	7.95
Total Other Income / (Expense), net	-8.58	1.08	-3.82	-23	0.84	-16	-17	1.54	-11	-6.50	-14
Interest & Investment Income	0.34	1.08	0.96	-45	0.44	-13	-19	-50	-0.18	-2.83	-2.03
Other Income / (Expense), net	-9.70	0.78	-3.12	-18	11	-2.57	2.05	19	3.85	6.66	-4.78
Income Tax Expense	53	74	72	65	75	51	53	47	57	49	51
Basic Earnings per Share	$2.49	$2.35	$2.12	$1.99	$2.04	$1.42	$1.49	$1.57	$1.58	$1.53	$1.44
Weighted Average Basic Shares Outstanding	146.72M	146.81M	146.86M	147.02M	146.96M	147.13M	147.08M	146.77M	146.91M	146.70M	146.43M
Diluted Earnings per Share	$2.48	$2.34	$2.11	$1.97	$2.04	$1.42	$1.49	$1.55	$1.58	$1.53	$1.43
Weighted Average Diluted Shares Outstanding	147.22M	147.48M	147.60M	147.55M	147.45M	147.55M	147.49M	147.46M	147.40M	147.41M	147.13M
Weighted Average Basic & Diluted Shares Outstanding	146.63M	146.87M	146.80M	146.93M	146.91M	147.09M	147.09M	147.07M	146.93M	146.91M	146.48M
Cash Dividends to Common per Share	$0.53	$0.53	$0.53	$0.48	$0.48	$0.48	$0.48	$0.44	$0.44	$0.44	$0.44

This table details how cash moves in and out of ResMed's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	6/30/2024	6/30/2023	6/30/2022	6/30/2021	6/30/2020	6/30/2019	6/30/2018	6/30/2017	6/30/2016	6/30/2015
Net Change in Cash & Equivalents	10	-46	-22	-168	316	-42	-633	91	14	-163
Net Cash From Operating Activities	1,401	693	351	737	802	459	505	414	548	409
Net Cash From Continuing Operating Activities	1,401	693	351	737	802	459	505	414	548	409
Net Income / (Loss) Continuing Operations	1,021	898	779	475	622	405	316	342	352	353
Consolidated Net Income / (Loss)	1,021	898	779	475	622	405	316	342	352	353
Depreciation Expense	177	165	160	157	155	151	120	112	87	73
Amortization Expense	39	32	34	35	27	0.00	0.00	-	-	-
Non-Cash Adjustments To Reconcile Net Income	119	60	86	69	97	81	60	39	50	48
Changes in Operating Assets and Liabilities, net	45	-462	-708	1.41	-98	-177	9.47	-80	59	-65
Net Cash From Investing Activities	-270	-1,160	-230	-158	-180	-1,076	-102	-82	-1,126	-143
Net Cash From Continuing Investing Activities	-270	-1,160	-230	-158	-180	-1,076	-102	-82	-1,126	-143
Purchase of Property, Plant & Equipment	-99	-120	-135	-103	-95	-69	-63	-62	-59	-63
Acquisitions	-149	-1,027	-64	-53	-39	-960	-9.78	-17	-1,051	-39
Purchase of Investments	-13	-32	-21	-22	-32	-47	-29	-6.46	-8.97	-42
Sale and/or Maturity of Investments	-8.70	19	-10	19	-14	-	-	3.32	-7.10	-
Net Cash From Financing Activities	-1,119	423	-128	-765	-317	581	-1,027	-263	613	-256
Net Cash From Continuing Financing Activities	-1,119	423	-128	-765	-317	581	-1,027	-263	613	-256
Repayment of Debt	-835	-405	-166	-612	-1,284	-712	-1,146	-545	-284	-182
Repurchase of Common Equity	-150	0.00	0.00	-	-	-23	-54	-	-102	-160
Payment of Dividends	-284	-261	-245	-230	-225	-213	-200	-198	-169	-158
Issuance of Debt	105	1,070	288	90	1,190	1,519	350	450	1,140	180
Issuance of Common Equity	53	49	47	38	48	37	39	38	28	39
Other Financing Activities, net	-8.76	-31	-52	-50	-46	-28	-15	-8.16	-	25
Effect of Exchange Rate Changes	-1.72	-2.15	-14	18	11	-5.56	-9.74	21	-21	-173
Cash Interest Paid	46	47	22	24	40	36	28	28	11	-
Cash Income Taxes Paid	278	217	478	221	180	243	171	93	69	49

This table details how cash moves in and out of ResMed's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	411	96	188	0.45	28	1.15	-19	-0.00	-25	46	-67
Net Cash From Operating Activities	579	309	326	440	402	273	286	237	283	129	45
Net Cash From Continuing Operating Activities	579	309	326	440	402	273	286	237	283	129	45
Net Income / (Loss) Continuing Operations	365	345	311	292	300	209	219	230	233	225	210
Consolidated Net Income / (Loss)	365	345	311	292	300	209	219	230	233	225	210
Depreciation Expense	44	46	45	44	43	45	45	47	44	38	36
Amortization Expense	8.24	9.46	8.98	11	11	8.59	8.51	8.44	8.43	7.77	7.76
Non-Cash Adjustments To Reconcile Net Income	29	23	20	36	6.08	54	23	16	12	11	22
Changes in Operating Assets and Liabilities, net	132	-115	-59	57	41	-44	-9.59	-63	-14	-153	-232
Net Cash From Investing Activities	-32	-37	2.15	-47	-33	-41	-149	-47	-28	-1,026	-59
Net Cash From Continuing Investing Activities	-32	-37	2.15	-47	-33	-41	-149	-47	-28	-1,026	-59
Purchase of Property, Plant & Equipment	-21	-21	-18	-25	-21	-23	-30	-34	-29	-27	-29
Acquisitions	-2.99	-3.50	-1.77	-21	-5.00	-8.71	-114	-5.81	-2.41	-996	-22
Purchase of Investments	-2.05	-20	18	-3.07	-2.39	-3.63	-3.68	-2.50	-13	-13	-4.29
Sale and/or Maturity of Investments	-5.95	7.42	4.13	2.58	-4.58	-5.46	-1.25	-3.77	16	10	-3.04
Net Cash From Financing Activities	-144	-148	-151	-393	-336	-239	-151	-189	-280	933	-42
Net Cash From Continuing Financing Activities	-144	-148	-151	-393	-336	-239	-151	-189	-280	933	-42
Repurchase of Common Equity	-75	-75	-50	-50	-50	-50	0.00	-	-	-	-
Payment of Dividends	-78	-78	-79	-72	-70	-71	-72	-67	-65	-65	-64
Issuance of Common Equity	9.02	27	8.38	28	4.89	20	0.98	23	0.98	22	2.61
Other Financing Activities, net	-0.36	-17	-0.39	0.87	-0.31	-7.80	-0.23	-0.02	-0.90	-30	-0.06
Effect of Exchange Rate Changes	7.96	-29	11	0.13	-5.30	8.42	-4.96	-2.33	-0.21	11	-11
Cash Interest Paid	14	-0.07	7.35	5.92	11	14	15	15	15	10	7.13
Cash Income Taxes Paid	-27	119	106	43	62	97	77	71	38	55	53

This table presents ResMed's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	6/30/2024	6/30/2023	6/30/2022	6/30/2021	6/30/2020	6/30/2019	6/30/2018	6/30/2017	6/30/2016	6/30/2015
Total Assets	6,872	6,752	5,096	4,728	4,587	4,108	3,064	3,468	3,257	2,182
Total Current Assets	2,358	2,368	1,931	1,575	1,523	1,145	1,066	1,644	1,420	1,408
Cash & Equivalents	238	228	274	295	463	147	189	822	731	717
Accounts Receivable	837	705	576	614	475	528	484	451	382	363
Inventories, net	822	998	744	457	417	350	269	268	224	247
Prepaid Expenses	460	437	338	208	75	120	125	103	82	81
Plant, Property, & Equipment, net	548	538	498	463	417	387	387	394	384	388
Total Noncurrent Assets	3,967	3,846	2,666	2,690	2,647	2,575	1,612	1,430	1,453	386
Goodwill	2,842	2,770	1,936	1,928	1,890	1,856	1,069	1,065	1,059	264
Intangible Assets	486	552	346	393	448	522	215	262	300	47
Noncurrent Deferred & Refundable Income Taxes	204	133	80	80	41	45	54	62	55	46
Other Noncurrent Operating Assets	435	390	304	289	267	151	274	42	38	28
Total Liabilities & Shareholders' Equity	6,872	6,752	5,096	4,728	4,587	4,108	3,064	3,468	3,257	2,182
Total Liabilities	2,008	2,622	1,735	1,842	2,090	2,035	1,005	1,508	1,562	594
Total Current Liabilities	911	759	689	912	603	556	511	360	638	266
Short-Term Debt	9.90	9.90	9.92	12	12	12	11	-	299	-
Accounts Payable	238	151	159	138	136	116	93	93	93	81
Accrued Expenses	378	366	345	321	270	266	186	186	157	133
Current Deferred Revenue	153	138	109	110	99	89	61	52	50	36
Current Deferred & Payable Income Tax Liabilities	108	72	45	308	65	73	160	29	39	16
Other Current Liabilities	25	22	22	24	21	0.00	-	-	-	-
Total Noncurrent Liabilities	1,098	1,863	1,046	931	1,488	1,479	494	1,148	924	328
Long-Term Debt	697	1,431	765	643	1,164	1,259	270	1,079	873	301
Noncurrent Deferred Revenue	137	156	144	154	200	207	210	53	40	21
Noncurrent Deferred & Payable Income Tax Liabilities	79	91	9.71	11	13	11	13	14	9.06	6.37
Other Noncurrent Operating Liabilities	184	185	126	122	110	2.06	0.92	2.43	1.21	0.00
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	4,864	4,130	3,361	2,886	2,497	2,072	2,059	1,960	1,695	1,587
Total Preferred & Common Equity	4,864	4,130	3,361	2,886	2,497	2,072	2,059	1,960	1,695	1,587
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	4,864	4,130	3,361	2,886	2,497	2,072	2,059	1,960	1,695	1,587
Common Stock	1,897	1,773	1,683	1,623	1,571	1,512	1,451	1,380	1,304	1,229
Retained Earnings	4,992	4,253	3,614	3,080	2,833	2,436	2,432	2,316	2,160	1,976
Treasury Stock	-1,773	-1,623	-1,623	-1,623	-1,623	-1,623	-1,600	-1,547	-1,547	-1,445
Accumulated Other Comprehensive Income / (Loss)	-252	-273	-313	-193	-284	-253	-224	-189	-223	-174

This table presents ResMed's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Total Assets	7,567	7,141	7,222	6,872	6,815	6,905	6,741	6,752	6,714	6,676	5,178
Total Current Assets	3,208	2,836	2,641	2,358	2,351	2,378	2,305	2,368	2,338	2,325	2,034
Cash & Equivalents	933	522	426	238	238	210	209	228	228	253	207
Accounts Receivable	908	860	811	837	779	730	692	705	686	672	620
Inventories, net	863	882	918	822	829	933	958	998	1,011	989	865
Prepaid Expenses	505	572	486	460	505	505	445	437	412	411	341
Plant, Property, & Equipment, net	535	520	560	548	540	552	534	538	529	523	487
Total Noncurrent Assets	3,823	3,785	4,021	3,967	3,924	3,975	3,902	3,846	3,847	3,828	2,656
Goodwill	2,849	2,805	2,886	2,842	2,836	2,862	2,812	2,770	2,784	2,767	1,939
Intangible Assets	430	438	479	486	501	528	563	552	570	587	338
Noncurrent Deferred & Refundable Income Taxes	217	209	221	204	162	156	138	133	96	86	81
Other Noncurrent Operating Assets	327	332	436	435	424	429	389	390	398	388	299
Total Liabilities & Shareholders' Equity	7,567	7,141	7,222	6,872	6,815	6,905	6,741	6,752	6,714	6,676	5,178
Total Liabilities	2,021	1,888	2,027	2,008	2,185	2,423	2,490	2,622	2,781	2,938	1,745
Total Current Liabilities	941	852	904	911	773	764	771	759	762	733	693
Short-Term Debt	9.91	9.91	9.90	9.90	9.90	9.90	9.91	9.90	9.90	9.90	9.91
Accounts Payable	223	220	249	238	177	202	177	151	162	196	181
Accrued Expenses	386	353	366	378	356	332	348	366	347	312	324
Current Deferred Revenue	160	157	157	153	151	149	147	138	141	134	108
Current Deferred & Payable Income Tax Liabilities	133	85	94	108	55	47	67	72	78	58	48
Other Current Liabilities	29	28	28	25	24	24	22	22	23	22	21
Total Noncurrent Liabilities	1,080	1,036	1,123	1,098	1,412	1,659	1,720	1,863	2,020	2,205	1,052
Long-Term Debt	663	663	668	697	997	1,217	1,352	1,431	1,576	1,791	785
Noncurrent Deferred Revenue	151	147	144	137	144	140	134	156	146	140	135
Noncurrent Deferred & Payable Income Tax Liabilities	79	77	84	79	87	89	88	91	113	108	12
Other Noncurrent Operating Liabilities	187	150	228	184	184	214	147	185	185	167	120
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	5,546	5,253	5,195	4,864	4,630	4,482	4,250	4,130	3,933	3,738	3,433
Total Preferred & Common Equity	5,546	5,253	5,195	4,864	4,630	4,482	4,250	4,130	3,933	3,738	3,433
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	5,546	5,253	5,195	4,864	4,630	4,482	4,250	4,130	3,933	3,738	3,433
Common Stock	1,991	1,958	1,925	1,897	1,849	1,824	1,792	1,773	1,730	1,711	1,702
Retained Earnings	5,779	5,492	5,225	4,992	4,770	4,540	4,402	4,253	4,088	3,920	3,760
Treasury Stock	-1,973	-1,898	-1,823	-1,773	-1,723	-1,673	-1,623	-1,623	-1,623	-1,623	-1,623
Accumulated Other Comprehensive Income / (Loss)	-251	-299	-132	-252	-265	-208	-320	-273	-262	-270	-406

This table displays calculated financial ratios and metrics derived from ResMed's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	6/30/2024	6/30/2023	6/30/2022	6/30/2021	6/30/2020	6/30/2019	6/30/2018	6/30/2017	6/30/2016	6/30/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	10.95%	18.02%	11.93%	8.11%	13.44%	11.38%	13.23%	12.40%	9.52%	7.97%
EBITDA Growth	12.90%	14.24%	6.77%	13.40%	36.08%	10.12%	20.51%	4.09%	6.59%	1.90%
EBIT Growth	13.50%	16.65%	7.92%	15.17%	40.27%	6.61%	24.05%	-0.93%	4.43%	2.34%
NOPAT Growth	15.53%	13.60%	67.28%	-29.33%	52.00%	37.71%	-5.76%	1.21%	3.81%	2.11%
Net Income Growth	13.75%	15.15%	64.26%	-23.67%	53.65%	28.20%	-7.80%	-2.87%	-0.14%	2.20%
EPS Growth	13.63%	14.91%	63.58%	-24.12%	52.50%	27.85%	-8.75%	-3.61%	0.81%	3.35%
Operating Cash Flow Growth	102.11%	97.44%	-52.34%	-8.17%	74.76%	-9.10%	21.97%	-24.43%	34.02%	0.31%
Free Cash Flow Firm Growth	292.53%	-386.21%	-56.57%	-33.16%	213.51%	-250.67%	47.12%	143.00%	-298.00%	52.10%
Invested Capital Growth	-0.19%	38.34%	19.00%	1.11%	0.44%	48.53%	-2.94%	3.78%	82.48%	1.50%
Revenue Q/Q Growth	2.21%	5.16%	1.09%	3.42%	2.26%	3.22%	2.94%	1.88%	3.70%	2.31%
EBITDA Q/Q Growth	4.68%	4.47%	-0.02%	1.74%	15.99%	-2.48%	3.54%	1.17%	6.03%	-0.68%
EBIT Q/Q Growth	5.53%	4.31%	0.04%	2.09%	16.43%	-4.89%	3.65%	1.21%	4.92%	-0.30%
NOPAT Q/Q Growth	8.42%	2.15%	1.51%	2.68%	16.76%	-5.51%	2.56%	6.84%	0.25%	0.76%
Net Income Q/Q Growth	6.53%	4.01%	-0.01%	3.78%	21.27%	-9.20%	2.67%	5.71%	-1.22%	-0.08%
EPS Q/Q Growth	6.46%	3.92%	-0.19%	3.51%	20.96%	-9.09%	2.82%	4.80%	-0.80%	0.41%
Operating Cash Flow Q/Q Growth	16.91%	29.50%	-29.51%	-12.34%	30.70%	2.78%	-2.11%	-1.48%	8.43%	-3.90%
Free Cash Flow Firm Q/Q Growth	23.04%	11.31%	-22.41%	-17.27%	29.79%	-5.84%	14.60%	155.72%	-848.63%	-9.37%
Invested Capital Q/Q Growth	-1.22%	1.00%	2.78%	1.13%	-2.15%	-0.45%	-0.96%	0.95%	53.62%	3.55%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	56.67%	55.78%	56.57%	57.53%	58.09%	57.32%	57.04%	58.15%	58.00%	60.24%
EBITDA Margin	32.62%	32.06%	33.12%	34.72%	33.10%	27.60%	27.91%	26.23%	28.32%	29.10%
Operating Margin	28.17%	26.80%	27.96%	28.27%	27.38%	22.22%	23.15%	20.60%	23.33%	24.38%
EBIT Margin	28.01%	27.38%	27.70%	28.73%	26.97%	21.81%	22.79%	20.80%	23.60%	24.75%
Profit (Net Income) Margin	21.79%	21.25%	21.78%	14.84%	21.02%	15.52%	13.49%	16.56%	19.17%	21.02%
Tax Burden Percent	80.72%	81.47%	81.15%	53.70%	84.80%	77.98%	60.54%	81.74%	80.17%	80.95%
Interest Burden Percent	96.38%	95.27%	96.89%	96.21%	91.92%	91.26%	97.75%	97.41%	101.30%	104.92%
Effective Tax Rate	19.28%	18.53%	18.85%	46.30%	15.20%	22.02%	39.46%	18.26%	19.83%	19.05%
Return on Invested Capital (ROIC)	19.96%	20.04%	22.84%	15.03%	21.44%	16.89%	15.02%	15.99%	20.80%	28.51%
ROIC Less NNEP Spread (ROIC-NNEP)	14.67%	17.16%	15.34%	13.03%	14.37%	9.15%	7.91%	14.34%	89.76%	24.28%
Return on Net Nonoperating Assets (RNNOA)	2.74%	3.93%	2.12%	2.60%	5.77%	2.69%	0.69%	2.74%	0.67%	-7.41%
Return on Equity (ROE)	22.70%	23.96%	24.96%	17.63%	27.21%	19.59%	15.70%	18.73%	21.47%	21.10%
Cash Return on Invested Capital (CROIC)	20.15%	-12.14%	5.49%	13.93%	21.00%	-22.16%	18.00%	12.28%	-37.60%	27.02%
Operating Return on Assets (OROA)	19.27%	19.52%	20.18%	19.72%	18.34%	15.86%	16.33%	12.78%	15.96%	18.29%
Return on Assets (ROA)	14.99%	15.15%	15.87%	10.19%	14.30%	11.28%	9.66%	10.18%	12.96%	15.54%
Return on Common Equity (ROCE)	22.70%	23.96%	24.96%	17.63%	27.21%	19.59%	15.70%	18.73%	21.47%	21.10%
Return on Equity Simple (ROE_SIMPLE)	20.99%	21.73%	23.19%	16.44%	24.90%	19.52%	15.33%	17.46%	20.79%	22.23%
Net Operating Profit after Tax (NOPAT)	1,065	922	812	485	687	452	328	348	344	331
NOPAT Margin	22.74%	21.84%	22.69%	15.18%	23.22%	17.33%	14.02%	16.84%	18.70%	19.73%
Net Nonoperating Expense Percent (NNEP)	5.29%	2.87%	7.50%	2.00%	7.07%	7.75%	7.11%	1.65%	-68.96%	4.23%
Cost of Revenue to Revenue	43.33%	44.22%	43.43%	42.47%	41.91%	42.68%	42.96%	41.85%	42.00%	39.76%
SG&A Expenses to Revenue	19.57%	20.70%	20.61%	20.97%	22.88%	24.75%	25.65%	26.80%	26.54%	28.51%
R&D to Revenue	6.56%	6.81%	7.09%	7.05%	6.83%	6.93%	6.63%	6.99%	6.45%	6.84%
Operating Expenses to Revenue	28.50%	28.98%	28.62%	29.26%	30.71%	35.10%	33.89%	37.54%	34.67%	35.87%
Earnings before Interest and Taxes (EBIT)	1,312	1,156	991	918	798	569	533	430	434	415
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	1,529	1,354	1,185	1,110	979	719	653	542	521	489
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	5.77	7.67	8.94	12.09	10.73	8.07	6.76	5.22	4.76	4.45
Price to Tangible Book Value (P/TBV)	18.26	39.26	27.85	61.73	169.08	0.00	17.97	16.15	24.01	5.54
Price to Revenue (P/Rev)	5.99	7.50	8.39	10.91	9.06	6.41	5.95	4.95	4.39	4.21
Price to Earnings (P/E)	27.48	35.31	38.54	73.53	43.12	41.31	44.12	29.90	22.88	20.02
Dividend Yield	1.01%	0.82%	0.82%	0.65%	0.84%	1.27%	1.44%	2.25%	2.09%	2.23%
Earnings Yield	3.64%	2.83%	2.60%	1.36%	2.32%	2.42%	2.27%	3.34%	4.37%	5.00%
Enterprise Value to Invested Capital (EV/IC)	5.35	6.16	7.91	10.86	8.57	5.58	6.51	4.73	3.98	5.68
Enterprise Value to Revenue (EV/Rev)	6.09	7.79	8.53	11.03	9.31	6.84	5.99	5.08	4.63	3.96
Enterprise Value to EBITDA (EV/EBITDA)	18.66	24.30	25.77	31.76	28.11	24.80	21.46	19.35	16.33	13.61
Enterprise Value to EBIT (EV/EBIT)	21.73	28.46	30.81	38.38	34.51	31.38	26.29	24.40	19.60	16.00
Enterprise Value to NOPAT (EV/NOPAT)	26.77	35.68	37.62	72.65	40.08	39.49	42.74	30.14	24.73	20.07
Enterprise Value to Operating Cash Flow (EV/OCF)	20.36	47.46	86.97	47.85	34.30	38.86	27.76	25.33	15.52	16.26
Enterprise Value to Free Cash Flow (EV/FCFF)	26.52	0.00	156.44	78.43	40.92	0.00	35.65	39.25	0.00	21.17
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.15	0.35	0.23	0.23	0.47	0.61	0.14	0.55	0.69	0.19
Long-Term Debt to Equity	0.14	0.35	0.23	0.22	0.47	0.61	0.13	0.55	0.52	0.19
Financial Leverage	0.19	0.23	0.14	0.20	0.40	0.29	0.09	0.19	0.01	-0.31
Leverage Ratio	1.51	1.58	1.57	1.73	1.90	1.74	1.63	1.84	1.66	1.36
Compound Leverage Factor	1.46	1.51	1.52	1.67	1.75	1.58	1.59	1.79	1.68	1.42
Debt to Total Capital	12.69%	25.87%	18.74%	18.51%	32.02%	38.01%	12.03%	35.49%	40.90%	15.92%
Short-Term Debt to Total Capital	0.18%	0.18%	0.24%	0.34%	0.33%	0.36%	0.49%	0.00%	10.44%	0.00%
Long-Term Debt to Total Capital	12.52%	25.69%	18.50%	18.17%	31.69%	37.66%	11.54%	35.49%	30.46%	15.92%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	87.31%	74.13%	81.26%	81.49%	67.98%	61.99%	87.97%	64.51%	59.10%	84.08%
Debt to EBITDA	0.46	1.06	0.65	0.59	1.20	1.77	0.43	1.99	2.25	0.62
Net Debt to EBITDA	0.31	0.90	0.42	0.32	0.73	1.56	0.14	0.47	0.85	-0.85
Long-Term Debt to EBITDA	0.46	1.06	0.65	0.58	1.19	1.75	0.41	1.99	1.68	0.62
Debt to NOPAT	0.66	1.56	0.96	1.35	1.71	2.81	0.86	3.10	3.41	0.91
Net Debt to NOPAT	0.44	1.32	0.62	0.74	1.04	2.49	0.28	0.74	1.28	-1.26
Long-Term Debt to NOPAT	0.65	1.55	0.94	1.33	1.70	2.79	0.82	3.10	2.54	0.91
Altman Z-Score	10.96	9.61	13.02	13.76	10.02	7.02	10.98	6.45	5.32	10.42
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.59	3.12	2.80	1.73	2.53	2.06	2.08	4.57	2.23	5.28
Quick Ratio	1.18	1.23	1.23	1.00	1.56	1.22	1.32	3.53	1.75	4.05
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	1,076	-559	195	449	673	-592	393	267	-622	314
Operating Cash Flow to CapEx	1,408.87%	579.33%	260.43%	717.27%	841.56%	668.10%	807.00%	665.48%	936.09%	654.14%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	19.02	17.09	-16.39	13.87	9.47	-55.47	54.33
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	31.18	20.38	12.70	17.81	14.66	48.90	70.76
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	26.83	17.96	10.80	15.60	12.46	43.67	59.94
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.69	0.71	0.73	0.69	0.68	0.73	0.72	0.61	0.68	0.74
Accounts Receivable Turnover	6.08	6.59	6.01	5.87	5.90	5.15	5.01	4.96	4.94	4.65
Inventory Turnover	2.23	2.14	2.59	3.11	3.23	3.60	3.74	3.51	3.28	3.24
Fixed Asset Turnover	8.63	8.15	7.44	7.26	7.35	6.74	5.99	5.31	4.76	4.08
Accounts Payable Turnover	10.45	12.05	10.45	9.92	9.85	10.67	10.84	9.33	8.89	8.02
Days Sales Outstanding (DSO)	60.07	55.35	60.71	62.17	61.91	70.87	72.85	73.52	73.91	78.50
Days Inventory Outstanding (DIO)	163.64	170.24	141.05	117.47	112.89	101.44	97.49	103.97	111.39	112.72
Days Payable Outstanding (DPO)	34.93	30.30	34.91	36.80	37.04	34.19	33.67	39.10	41.05	45.53
Cash Conversion Cycle (CCC)	188.79	195.30	166.85	142.84	137.76	138.11	136.67	138.39	144.25	145.69
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	5,333	5,343	3,862	3,246	3,210	3,196	2,152	2,217	2,136	1,171
Invested Capital Turnover	0.88	0.92	1.01	0.99	0.92	0.97	1.07	0.95	1.11	1.44
Increase / (Decrease) in Invested Capital	-10	1,481	617	36	14	1,044	-65	81	966	17
Enterprise Value (EV)	28,523	32,904	30,537	35,252	27,518	17,839	14,018	10,490	8,505	6,647
Market Capitalization	28,054	31,691	30,036	34,892	26,805	16,715	13,925	10,233	8,063	7,064
Book Value per Share	$33.11	$28.11	$22.97	$19.83	$17.26	$14.45	$14.42	$13.82	$12.07	$11.26
Tangible Book Value per Share	$10.46	$5.49	$7.37	$3.88	$1.10	($2.14)	$5.43	$4.47	$2.39	$9.05
Total Capital	5,571	5,571	4,136	3,541	3,673	3,343	2,340	3,039	2,868	1,888
Total Debt	707	1,441	775	655	1,176	1,271	281	1,079	1,173	301
Total Long-Term Debt	697	1,431	765	643	1,164	1,259	270	1,079	873	301
Net Debt	469	1,213	502	360	713	1,124	93	257	441	-417
Capital Expenditures (CapEx)	99	120	135	103	95	69	63	62	59	63
Debt-free, Cash-free Net Working Capital (DFCFNWC)	1,219	1,391	978	380	470	454	377	462	350	424
Debt-free Net Working Capital (DFNWC)	1,457	1,619	1,252	675	933	601	566	1,284	1,081	1,141
Net Working Capital (NWC)	1,447	1,609	1,242	663	921	589	554	1,284	782	1,141
Net Nonoperating Expense (NNE)	44	25	32	11	65	47	12	5.77	-8.51	-22
Net Nonoperating Obligations (NNO)	469	1,213	502	360	713	1,124	93	257	441	-417
Total Depreciation and Amortization (D&A)	216	198	194	192	181	151	120	112	87	73
Debt-free, Cash-free Net Working Capital to Revenue	26.01%	32.95%	27.34%	11.88%	15.88%	17.43%	16.12%	22.35%	19.02%	25.26%
Debt-free Net Working Capital to Revenue	31.10%	38.34%	34.99%	21.11%	31.54%	23.07%	24.18%	62.12%	58.80%	67.98%
Net Working Capital to Revenue	30.89%	38.11%	34.72%	20.74%	31.14%	22.61%	23.69%	62.12%	42.52%	67.98%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$6.94	$6.12	$5.34	$3.27	$4.31	$2.83	$2.21	$2.42	$2.51	$2.51
Adjusted Weighted Average Basic Shares Outstanding	147.02M	146.77M	146.07M	145.31M	144.34M	143.11M	142.76M	141.36M	140.24M	140.47M
Adjusted Diluted Earnings per Share	$6.92	$6.09	$5.30	$3.24	$4.27	$2.80	$2.19	$2.40	$2.49	$2.47
Adjusted Weighted Average Diluted Shares Outstanding	147.55M	147.46M	147.04M	146.45M	145.65M	144.48M	143.99M	142.45M	141.67M	142.69M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	146.93M	147.07M	146.42M	145.68K	144.90M	143.67M	142.68M	142.21M	140.70M	140.52M
Normalized Net Operating Profit after Tax (NOPAT)	1,117	939	813	490	686	491	339	373	349	331
Normalized NOPAT Margin	23.85%	22.23%	22.73%	15.32%	23.20%	18.84%	14.49%	18.06%	19.00%	19.73%
Pre Tax Income Margin	27.00%	26.09%	26.84%	27.64%	24.79%	19.91%	22.28%	20.26%	23.91%	25.96%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	38.87	20.26	15.72	18.81	15.23	38.72	71.91
NOPAT to Interest Expense	0.00	0.00	0.00	20.54	17.45	12.49	11.57	12.33	30.69	57.34
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	34.53	17.84	13.82	16.60	13.02	33.50	61.09
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	16.19	15.02	10.59	9.36	10.12	25.47	46.52
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	27.78%	29.04%	31.48%	48.52%	36.26%	52.55%	63.37%	57.85%	48.06%	44.69%
Augmented Payout Ratio	42.47%	29.04%	31.48%	48.52%	36.26%	58.20%	80.42%	57.85%	77.02%	90.12%

This table displays calculated financial ratios and metrics derived from ResMed's official financial filings.

Metric	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	7.92%	10.26%	11.08%	9.01%	7.17%	12.48%	16.00%	22.66%	29.20%	15.52%	5.12%
EBITDA Growth	6.32%	45.42%	27.12%	19.58%	23.32%	-1.96%	9.36%	19.91%	24.93%	12.77%	0.59%
EBIT Growth	7.92%	53.39%	32.01%	23.41%	26.76%	-5.00%	7.41%	19.41%	29.91%	17.01%	2.04%
NOPAT Growth	24.25%	55.26%	34.98%	36.36%	24.11%	-3.85%	5.09%	9.15%	30.37%	8.89%	7.58%
Net Income Growth	21.48%	65.05%	41.90%	27.25%	29.24%	-7.16%	4.25%	17.74%	29.88%	11.48%	3.37%
EPS Growth	21.57%	64.79%	41.61%	27.10%	29.11%	-7.19%	4.20%	17.42%	29.51%	11.68%	2.88%
Operating Cash Flow Growth	43.93%	13.12%	13.71%	85.36%	42.28%	112.10%	541.00%	198.71%	140.61%	-41.50%	168.02%
Free Cash Flow Firm Growth	153.50%	4,977.63%	123.59%	125.68%	114.82%	100.61%	-371.13%	-207.51%	-255.89%	-9,614.35%	-584.33%
Invested Capital Growth	-2.08%	-1.72%	0.80%	-0.19%	2.05%	4.03%	34.36%	38.34%	40.79%	45.55%	13.09%
Revenue Q/Q Growth	0.75%	4.70%	0.11%	2.19%	2.94%	5.49%	-1.76%	0.46%	8.04%	8.78%	3.89%
EBITDA Q/Q Growth	-1.15%	8.22%	4.88%	-5.24%	35.21%	-5.40%	-1.34%	-2.28%	7.50%	5.53%	8.17%
EBIT Q/Q Growth	-0.35%	8.80%	5.90%	-6.02%	41.64%	-6.36%	-1.00%	-3.47%	6.16%	5.87%	10.06%
NOPAT Q/Q Growth	8.38%	9.31%	0.97%	3.87%	35.43%	-4.97%	2.01%	-5.46%	4.91%	3.86%	5.95%
Net Income Q/Q Growth	5.93%	10.68%	6.54%	-2.75%	43.91%	-4.84%	-4.46%	-1.22%	3.37%	6.86%	7.90%
EPS Q/Q Growth	5.98%	10.90%	7.11%	-3.43%	43.66%	-4.70%	-3.87%	-1.90%	3.27%	6.99%	8.33%
Operating Cash Flow Q/Q Growth	87.50%	-5.20%	-26.03%	9.47%	47.35%	-4.70%	20.57%	-15.97%	119.66%	188.02%	-43.81%
Free Cash Flow Firm Q/Q Growth	10.70%	61.69%	-15.75%	68.12%	2,117.28%	100.75%	8.29%	3.00%	9.32%	-484.03%	40.14%
Invested Capital Q/Q Growth	-2.17%	-0.78%	2.12%	-1.22%	-1.81%	1.77%	1.11%	1.00%	0.09%	31.45%	4.11%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	59.33%	58.60%	58.57%	58.50%	57.88%	55.64%	54.44%	55.02%	55.31%	56.08%	56.91%
EBITDA Margin	36.27%	36.96%	35.76%	34.14%	36.81%	28.03%	31.25%	31.12%	31.99%	32.15%	33.15%
Operating Margin	33.00%	32.54%	31.63%	31.17%	31.29%	23.66%	26.22%	24.53%	26.92%	27.10%	29.02%
EBIT Margin	32.25%	32.60%	31.38%	29.66%	32.25%	23.44%	26.40%	26.20%	27.27%	27.75%	28.51%
Profit (Net Income) Margin	28.26%	26.88%	25.43%	23.89%	25.10%	17.96%	19.91%	20.47%	20.82%	21.76%	22.15%
Tax Burden Percent	87.39%	82.38%	81.19%	81.69%	80.04%	80.48%	80.61%	82.97%	80.34%	82.18%	80.40%
Interest Burden Percent	100.27%	100.07%	99.82%	98.61%	97.26%	95.21%	93.52%	94.16%	95.03%	95.41%	96.62%
Effective Tax Rate	12.61%	17.62%	18.81%	18.31%	19.96%	19.52%	19.39%	17.03%	19.66%	17.82%	19.60%
Return on Invested Capital (ROIC)	27.11%	24.23%	22.76%	22.35%	21.48%	15.90%	19.62%	18.68%	19.20%	18.80%	22.32%
ROIC Less NNEP Spread (ROIC-NNEP)	24.16%	24.38%	22.32%	20.07%	21.55%	14.92%	18.07%	18.82%	18.21%	18.28%	20.31%
Return on Net Nonoperating Assets (RNNOA)	1.21%	2.92%	3.32%	3.75%	5.35%	4.65%	4.09%	4.31%	4.64%	5.40%	3.52%
Return on Equity (ROE)	28.32%	27.16%	26.08%	26.10%	26.84%	20.56%	23.72%	22.98%	23.84%	24.20%	25.83%
Cash Return on Invested Capital (CROIC)	27.23%	25.02%	20.34%	20.15%	16.36%	13.20%	-9.51%	-12.14%	-13.92%	-18.12%	9.56%
Operating Return on Assets (OROA)	22.52%	22.87%	21.60%	20.40%	21.86%	15.55%	19.38%	18.68%	18.85%	18.30%	20.86%
Return on Assets (ROA)	19.73%	18.86%	17.51%	16.43%	17.01%	11.91%	14.61%	14.59%	14.39%	14.35%	16.21%
Return on Common Equity (ROCE)	28.32%	27.16%	26.08%	26.10%	26.84%	20.56%	23.72%	22.98%	23.84%	24.20%	25.83%
Return on Equity Simple (ROE_SIMPLE)	23.68%	23.77%	21.42%	0.00%	20.70%	19.87%	21.33%	0.00%	21.94%	21.65%	22.91%
Net Operating Profit after Tax (NOPAT)	373	344	314	311	300	221	233	228	242	230	222
NOPAT Margin	28.84%	26.81%	25.68%	25.46%	25.05%	19.04%	21.13%	20.35%	21.63%	22.27%	23.33%
Net Nonoperating Expense Percent (NNEP)	2.94%	-0.15%	0.44%	2.28%	-0.06%	0.98%	1.56%	-0.15%	0.99%	0.53%	2.01%
Return On Investment Capital (ROIC_SIMPLE)	5.99%	5.80%	-	-	-	3.88%	-	-	-	-	-
Cost of Revenue to Revenue	40.67%	41.40%	41.43%	41.50%	42.12%	44.36%	45.56%	44.98%	44.69%	43.92%	43.09%
SG&A Expenses to Revenue	18.99%	18.85%	19.52%	19.80%	19.21%	19.11%	20.22%	21.38%	20.45%	20.48%	20.41%
R&D to Revenue	6.50%	6.35%	6.49%	6.61%	6.44%	6.35%	6.87%	6.96%	6.84%	6.76%	6.65%
Operating Expenses to Revenue	26.33%	26.05%	26.94%	27.33%	26.58%	31.98%	28.22%	30.49%	28.39%	28.97%	27.89%
Earnings before Interest and Taxes (EBIT)	417	418	384	363	386	273	291	294	305	287	271
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	468	474	438	418	441	326	344	349	357	332	315
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	5.93	6.39	6.90	5.77	6.26	5.59	5.06	7.67	8.06	8.02	9.14
Price to Tangible Book Value (P/TBV)	14.50	16.70	19.60	18.26	22.43	22.96	24.60	39.26	54.73	78.05	27.14
Price to Revenue (P/Rev)	6.55	6.81	7.46	5.99	6.32	5.57	4.92	7.50	7.89	7.97	8.65
Price to Earnings (P/E)	25.03	26.88	32.23	27.48	30.25	28.15	23.74	35.31	36.73	37.04	39.89
Dividend Yield	0.92%	0.88%	0.81%	1.01%	0.95%	1.08%	1.23%	0.82%	0.81%	0.84%	0.79%
Earnings Yield	3.99%	3.72%	3.10%	3.64%	3.31%	3.55%	4.21%	2.83%	2.72%	2.70%	2.51%
Enterprise Value to Invested Capital (EV/IC)	6.17	6.24	6.63	5.35	5.51	4.74	4.20	6.16	6.25	5.96	7.95
Enterprise Value to Revenue (EV/Rev)	6.50	6.84	7.51	6.09	6.49	5.79	5.18	7.79	8.23	8.38	8.82
Enterprise Value to EBITDA (EV/EBITDA)	18.14	19.05	22.27	18.66	20.38	18.95	16.39	24.30	25.51	25.74	26.92
Enterprise Value to EBIT (EV/EBIT)	20.62	21.74	25.70	21.73	23.93	22.45	19.28	28.46	29.82	30.36	32.06
Enterprise Value to NOPAT (EV/NOPAT)	24.30	26.57	31.49	26.77	30.29	28.21	24.29	35.68	36.62	37.25	38.61
Enterprise Value to Operating Cash Flow (EV/OCF)	19.73	22.84	25.07	20.36	24.83	24.17	24.25	47.46	61.75	85.16	69.25
Enterprise Value to Free Cash Flow (EV/FCFF)	22.42	24.73	32.73	26.52	34.04	36.64	0.00	0.00	0.00	0.00	88.24
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.12	0.13	0.13	0.15	0.22	0.27	0.32	0.35	0.40	0.48	0.23
Long-Term Debt to Equity	0.12	0.13	0.13	0.14	0.22	0.27	0.32	0.35	0.40	0.48	0.23
Financial Leverage	0.05	0.12	0.15	0.19	0.25	0.31	0.23	0.23	0.25	0.30	0.17
Leverage Ratio	1.41	1.44	1.48	1.51	1.58	1.65	1.55	1.58	1.61	1.66	1.53
Compound Leverage Factor	1.42	1.44	1.48	1.49	1.54	1.57	1.45	1.49	1.53	1.58	1.48
Debt to Total Capital	10.82%	11.35%	11.54%	12.69%	17.86%	21.49%	24.26%	25.87%	28.74%	32.51%	18.81%
Short-Term Debt to Total Capital	0.16%	0.17%	0.17%	0.18%	0.18%	0.17%	0.18%	0.18%	0.18%	0.18%	0.23%
Long-Term Debt to Total Capital	10.66%	11.19%	11.37%	12.52%	17.69%	21.32%	24.08%	25.69%	28.56%	32.33%	18.58%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	89.18%	88.65%	88.46%	87.31%	82.14%	78.51%	75.74%	74.13%	71.26%	67.49%	81.19%
Debt to EBITDA	0.37	0.38	0.42	0.46	0.69	0.89	0.98	1.06	1.22	1.47	0.67
Net Debt to EBITDA	-0.14	0.09	0.15	0.31	0.53	0.74	0.83	0.90	1.05	1.26	0.50
Long-Term Debt to EBITDA	0.37	0.37	0.41	0.46	0.68	0.88	0.98	1.06	1.22	1.46	0.66
Debt to NOPAT	0.50	0.53	0.59	0.66	1.02	1.33	1.46	1.56	1.76	2.13	0.96
Net Debt to NOPAT	-0.19	0.12	0.22	0.44	0.78	1.10	1.23	1.32	1.50	1.83	0.71
Long-Term Debt to NOPAT	0.49	0.52	0.58	0.65	1.01	1.32	1.45	1.55	1.75	2.12	0.95
Altman Z-Score	12.04	12.96	12.76	10.51	10.08	8.19	7.16	9.19	8.72	7.94	12.99
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.41	3.33	2.92	2.59	3.04	3.11	2.99	3.12	3.07	3.17	2.94
Quick Ratio	1.96	1.62	1.37	1.18	1.32	1.23	1.17	1.23	1.20	1.26	1.19
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	485	438	271	322	191	8.63	-1,149	-1,252	-1,291	-1,424	-244
Operating Cash Flow to CapEx	2,782.56%	1,494.98%	1,824.76%	1,768.88%	1,897.18%	1,168.30%	953.16%	689.24%	980.55%	470.33%	153.71%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	17.35	0.00	0.00	0.00	-86.29	-137.74	-34.18
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	36.46	0.00	0.00	0.00	18.88	12.44	6.26
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	34.54	0.00	0.00	0.00	16.96	9.80	2.19
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.70	0.70	0.69	0.69	0.68	0.66	0.73	0.71	0.69	0.66	0.73
Accounts Receivable Turnover	5.95	6.20	6.39	6.08	6.26	6.43	6.66	6.59	6.72	6.28	6.06
Inventory Turnover	2.45	2.26	2.17	2.23	2.20	2.10	2.15	2.14	2.09	2.06	2.28
Fixed Asset Turnover	9.34	9.19	8.79	8.63	8.58	8.38	8.57	8.15	7.71	7.52	7.59
Accounts Payable Turnover	10.36	9.70	9.55	10.45	11.95	10.15	10.93	12.05	11.26	9.07	8.82
Days Sales Outstanding (DSO)	61.31	58.89	57.08	60.07	58.34	56.81	54.77	55.35	54.30	58.11	60.22
Days Inventory Outstanding (DIO)	149.10	161.61	168.26	163.64	165.73	173.49	169.74	170.24	174.32	177.13	159.88
Days Payable Outstanding (DPO)	35.25	37.63	38.23	34.93	30.55	35.96	33.38	30.30	32.41	40.26	41.40
Cash Conversion Cycle (CCC)	175.17	182.86	187.10	188.79	193.52	194.34	191.13	195.30	196.21	194.98	178.70
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	5,286	5,404	5,446	5,333	5,399	5,498	5,403	5,343	5,290	5,286	4,021
Invested Capital Turnover	0.94	0.90	0.89	0.88	0.86	0.84	0.93	0.92	0.89	0.84	0.96
Increase / (Decrease) in Invested Capital	-113	-94	43	-10	108	213	1,382	1,481	1,533	1,654	465
Enterprise Value (EV)	32,616	33,722	36,120	28,523	29,763	26,085	22,676	32,904	33,055	31,527	31,955
Market Capitalization	32,876	33,571	35,869	28,054	28,994	25,069	21,524	31,691	31,697	29,979	31,367
Book Value per Share	$37.76	$35.78	$35.36	$33.11	$31.48	$30.47	$28.90	$28.11	$26.77	$25.52	$23.44
Tangible Book Value per Share	$15.44	$13.69	$12.46	$10.46	$8.79	$7.42	$5.95	$5.49	$3.94	$2.62	$7.89
Total Capital	6,219	5,926	5,873	5,571	5,637	5,709	5,612	5,571	5,518	5,539	4,228
Total Debt	673	673	677	707	1,007	1,227	1,361	1,441	1,586	1,801	795
Total Long-Term Debt	663	663	668	697	997	1,217	1,352	1,431	1,576	1,791	785
Net Debt	-260	151	251	469	769	1,016	1,152	1,213	1,358	1,547	588
Capital Expenditures (CapEx)	21	21	18	25	21	23	30	34	29	27	29
Debt-free, Cash-free Net Working Capital (DFCFNWC)	1,345	1,472	1,321	1,219	1,350	1,414	1,335	1,391	1,358	1,349	1,144
Debt-free Net Working Capital (DFNWC)	2,278	1,994	1,747	1,457	1,588	1,624	1,544	1,619	1,586	1,602	1,351
Net Working Capital (NWC)	2,268	1,984	1,737	1,447	1,578	1,614	1,534	1,609	1,576	1,592	1,341
Net Nonoperating Expense (NNE)	7.49	-0.89	3.10	19	-0.67	13	14	-1.27	9.07	5.34	11
Net Nonoperating Obligations (NNO)	-260	151	251	469	769	1,016	1,152	1,213	1,358	1,547	588
Total Depreciation and Amortization (D&A)	52	56	54	55	55	53	53	55	53	46	44
Debt-free, Cash-free Net Working Capital to Revenue	26.79%	29.88%	27.47%	26.01%	29.45%	31.39%	30.50%	32.95%	33.82%	35.85%	31.56%
Debt-free Net Working Capital to Revenue	45.36%	40.48%	36.34%	31.10%	34.64%	36.05%	35.28%	38.34%	39.50%	42.58%	37.27%
Net Working Capital to Revenue	45.16%	40.27%	36.13%	30.89%	34.43%	35.83%	35.06%	38.11%	39.25%	42.32%	37.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$2.49	$2.35	$2.12	$1.99	$2.04	$1.42	$1.49	$1.57	$1.58	$1.53	$1.44
Adjusted Weighted Average Basic Shares Outstanding	146.72M	146.81M	146.86M	147.02M	146.96M	147.13M	147.08M	146.77M	146.91M	146.70M	146.43M
Adjusted Diluted Earnings per Share	$2.48	$2.34	$2.11	$1.97	$2.04	$1.42	$1.49	$1.55	$1.58	$1.53	$1.43
Adjusted Weighted Average Diluted Shares Outstanding	147.22M	147.48M	147.60M	147.55M	147.45M	147.55M	147.49M	147.46M	147.40M	147.41M	147.13M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	146.63M	146.87M	146.80M	146.93M	146.91M	147.09M	147.09M	147.07M	146.93M	146.91M	146.48M
Normalized Net Operating Profit after Tax (NOPAT)	373	344	314	311	300	273	233	228	242	237	222
Normalized NOPAT Margin	28.84%	26.81%	25.68%	25.46%	25.05%	23.48%	21.13%	20.35%	21.63%	22.94%	23.33%
Pre Tax Income Margin	32.34%	32.63%	31.32%	29.25%	31.36%	22.31%	24.69%	24.67%	25.91%	26.48%	27.55%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	35.01	0.00	0.00	0.00	20.35	27.75	37.98
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	27.19	0.00	0.00	0.00	16.14	22.27	31.08
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	33.09	0.00	0.00	0.00	18.42	25.10	33.91
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	25.27	0.00	0.00	0.00	14.22	19.63	27.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	23.20%	23.82%	26.10%	27.78%	29.09%	30.80%	29.57%	29.04%	29.56%	31.11%	31.61%
Augmented Payout Ratio	42.24%	41.84%	44.07%	42.47%	39.53%	36.42%	29.57%	29.04%	29.56%	31.11%	31.61%

Frequently Asked Questions About ResMed's Financials

When does ResMed's fiscal year end?

According to the most recent income statement we have on file, ResMed's financial year ends in June. Their financial year 2024 ended on June 30, 2024.

How has ResMed's net income changed over the last 9 years?

ResMed's net income appears to be on an upward trend, with a most recent value of $1.02 billion in 2024, rising from $352.89 million in 2015. The previous period was $897.56 million in 2023. See ResMed's forecast for analyst expectations on what’s next for the company.

What is ResMed's operating income?

ResMed's total operating income in 2024 was $1.32 billion, based on the following breakdown:

Total Gross Profit: $2.66 billion
Total Operating Expenses: $1.34 billion

How has ResMed revenue changed over the last 9 years?

Over the last 9 years, ResMed's total revenue changed from $1.68 billion in 2015 to $4.69 billion in 2024, a change of 179.1%.

How much debt does ResMed have?

ResMed's total liabilities were at $2.01 billion at the end of 2024, a 23.4% decrease from 2023, and a 237.8% increase since 2015.

How much cash does ResMed have?

In the past 9 years, ResMed's cash and equivalents has ranged from $147.13 million in 2019 to $821.94 million in 2017, and is currently $238.36 million as of their latest financial filing in 2024.

How has ResMed's book value per share changed over the last 9 years?

Over the last 9 years, ResMed's book value per share changed from 11.26 in 2015 to 33.11 in 2024, a change of 193.9%.

Related Companies

This page (NYSE:RMD) was last updated on 5/27/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ResMed (RMD) Financials

Frequently Asked Questions About ResMed's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ResMed (RMD) Financials

Annual Income Statements for ResMed

Quarterly Income Statements for ResMed

Annual Cash Flow Statements for ResMed

Quarterly Cash Flow Statements for ResMed

Annual Balance Sheets for ResMed

Quarterly Balance Sheets for ResMed

Annual Metrics And Ratios for ResMed

Quarterly Metrics And Ratios for ResMed

Frequently Asked Questions About ResMed's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools